These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32886340)

  • 41. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D; Feinn R; Engmann L; Nulsen J; Budinetz T; Benadiva C
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The initial flare-up induced by gonadotropin releasing hormone agonist may serve as a predictor of ovarian response in the current IVF-ET treatment cycle in normogonadotropic women aged 40-48 years.
    Avrech OM; Royburt M; Sabah G; Zukerman Z; Pinkas H; Amit S; Ovadia J; Fisch B
    J Assist Reprod Genet; 1996 May; 13(5):395-400. PubMed ID: 8739055
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Which factors are most predictive for live birth after in vitro fertilization and intracytoplasmic sperm injection (IVF/ICSI) treatments? Analysis of 100 prospectively recorded variables in 8,400 IVF/ICSI single-embryo transfers.
    Vaegter KK; Lakic TG; Olovsson M; Berglund L; Brodin T; Holte J
    Fertil Steril; 2017 Mar; 107(3):641-648.e2. PubMed ID: 28108009
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction.
    Ku SY; Suh CS; Kim SH; Choi YM; Kim JG; Moon SY
    Eur J Obstet Gynecol Reprod Biol; 2003 Jul; 109(1):55-9. PubMed ID: 12818444
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles?
    Requena A; Landeras JL; Martínez-Navarro L; Calatayud C; Sánchez F; Maldonado V; Muñoz M; Fernández M; González A; López S; López R; Pacheco A; Calderón G; Martínez V
    Hum Fertil (Camb); 2010 Mar; 13(1):41-9. PubMed ID: 20384441
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Are intracytoplasmic sperm injection and high serum estradiol compounding risk factors for adverse obstetric outcomes in assisted reproductive technology?
    Royster GD; Krishnamoorthy K; Csokmay JM; Yauger BJ; Chason RJ; DeCherney AH; Wolff EF; Hill MJ
    Fertil Steril; 2016 Aug; 106(2):363-370.e3. PubMed ID: 27172401
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low LH level does not indicate poor IVF cycle outcomes with GnRh-a single trigger: a retrospective analysis.
    Li XF; Wang QF; He QQ; Wang XJ; Lv XY; Tang XJ; Zhong ZH; Ding YB; Wan Q
    BMC Pregnancy Childbirth; 2022 Dec; 22(1):951. PubMed ID: 36539727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is inversely correlated with a mature oocyte yield and can predict "low responders".
    Ho JY; Guu HF; Yi YC; Chen MJ; Ho ES
    Fertil Steril; 2005 Apr; 83(4):883-8. PubMed ID: 15820795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles.
    Lai Q; Zhang H; Zhu G; Li Y; Jin L; He L; Zhang Z; Yang P; Yu Q; Zhang S; Xu JF; Wang CY
    Int J Clin Exp Pathol; 2013; 6(9):1903-10. PubMed ID: 24040457
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Should progesterone on the human chorionic gonadotropin day still be measured?
    Martinez F; Rodriguez I; Devesa M; Buxaderas R; Gómez MJ; Coroleu B
    Fertil Steril; 2016 Jan; 105(1):86-92. PubMed ID: 26453983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
    Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fertilization and embryo development with spermatozoa obtained from testicular sperm extraction into oocytes generated from human chorionic gonadotropin-primed in vitro maturation cycles.
    Son WY; Chung JT; Henderson S; Reinblatt S; Buckett W; Chan PT; Holzer H
    Fertil Steril; 2013 Oct; 100(4):989-93. PubMed ID: 23806848
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Progesterone levels on the human chorionic gonadotropin trigger day affect the pregnancy rates for embryos transferred at different stages of development in both general and selected IVF/ICSI populations.
    Merviel P; Bouée S; Jacamon AS; Chabaud JJ; Le Martelot MT; Roche S; Rince C; Drapier H; Perrin A; Beauvillard D
    BMC Pregnancy Childbirth; 2021 May; 21(1):363. PubMed ID: 33957886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual trigger using recombinant HCG and gonadotropin-releasing hormone agonist improve oocyte maturity and embryo grading for normal responders in GnRH antagonist cycles: Randomized controlled trial.
    Ali SS; Elsenosy E; Sayed GH; Farghaly TA; Youssef AA; Badran E; Abbas AM; Abdelaleem AA
    J Gynecol Obstet Hum Reprod; 2020 May; 49(5):101728. PubMed ID: 32173633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer.
    Propst AM; Bates GW; Robinson RD; Arthur NJ; Martin JE; Neal GS
    Fertil Steril; 2006 Jul; 86(1):58-63. PubMed ID: 16753156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-dose GnRH antagonist protocol is as effective as the long GnRH agonist protocol in unselected patients undergoing in vitro fertilization and embryo transfer.
    Huang SY; Huang HY; Yu HT; Wang HS; Chen CK; Lee CL; Soong YK
    Taiwan J Obstet Gynecol; 2011 Dec; 50(4):432-5. PubMed ID: 22212313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Exploration of the value of progesterone and progesterone/estradiol ratio on the hCG trigger day in predicting pregnancy outcomes of PCOS patients undergoing IVF/ICSI: a retrospective cohort study.
    Yang Y; Liu B; Wu G; Yang J
    Reprod Biol Endocrinol; 2021 Dec; 19(1):184. PubMed ID: 34893087
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.